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Taxol (paclitaxel), a complex polyoxygenated diterpene isolated originally from the bark of Taxus
brevifolia is a promising anticancer agent in the treatment of ovarian and breast cancer. The molecule has
been extensively modified during the last few YC3rsin a bid to enhance its water solubility and to improve
its therapeutic profile. The present review gives an account of the recent developments in the structure
modifications of taxol and comments on the structure activity relationships of the analogues.
Natural products are the organic molecules which
are elaborated by living tissues derived from higher
plants, fungi, microbes, marine organisms and ani-
mals and exhibit a remarkably wide range of chemi-
cal diversity and a multiplicity of biological
properties. From time immemorial natural resources
have been in use for combating human ailments. Over
the last fifteen years interest in drugs of plant origin
has been reviving and growing steadily, and the drug
researchers are exploring the potential of natural
products for the cure of still unsurmountable diseases
like cancer and AIDS.
Cancer is a disease characterised by unregulated
proliferation of cells It is a growing public health
menace and more than six million new cases of this
disease are reported every year. It was in the year
1960 that a systematic screening programme for
antineoplastic agents of plant origin was initiated in
National Cancer Institute, USA under Dr J.H. Hart-
well. Plant samples collected at random by the US
Department of Agriculture were supplied for antitu-
mour screening. During such screening, the bark of
Pacific yew, Tanis brevifolia, showed activity
against a number of cell lines. Using bioactivity-
guided fractionation, the active principle, then named
'When originally discovered the generic name given was taxol,
before marketing Bristol-Myers Squibb Co. in United States
retained this name as their registered trademark and a new generic
name paclitaxel was given. In the present communication, how-







taxol, was isolated in 1967 and the structure] was
elucidated in 1971 by Wani et all. Taxol is a novel
highly functionalised diterpenoid comprising a tax-
ane nucleus with four ester groups attached to it. It
may be named as 5p, 20-epoxy-l, 2o',4,7p, lOp, 130,-
hexahydroxytax-ll-en-9-one-4, 10-diacetate-2-ben
zoate 13-ester with (2R,3S)-N-benzoyl-3-
phenylisoserin. It took more than two decades for
taxol to reach the clinics after its discovery. In De-
cember 1992, the drug was approved by the US FDA
as second line of therapy for platinum-resistant ad-
vanced ovarian cancer. Later, in April 1994 taxol was
cleared for metastatic breast cancer. The activity
profile includes its activity against murine
B16,Ll210,P388 and Pl534 Leukaemias. It is also
active against Walker 256 Carcinoma, Sarcoma 180
and Lewis lung tumour cell Iines/. Taxol has proved
efficacious against a number ofleukaemias and solid
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tumours in xenograft:s including those in breast,
ovary, brain and lung".
The mechanism of action oftaxol has been exten-
sively studiedl-13 In precise, the mode of action of
taxol involves promotion of polymerization of the
tubulin thereby promoting the formation of ex-
tremely stable and nonfunctional microtubules re-
sulting in cell death.
The two factors which have prompted medicinal
chemists to modify the structure of taxol are the low
water solubility (0.03 mg/ml.)!" of this compound
thus hampering its formulation, and undesirable side-
effects and multidrug resistance. Efforts have been
made to prepare analogues with better pharmacologi-
cal properties and/or activity spectra against various
types of tumour. Some excellent reviews covering
chemistry and structure- activity relationship studies
on taxol have appeared recentlyI5-19. The present
review gives an account of the recent developments,
covering the literature published mainly during the
last three years, towards structure modifications of
taxol leading to newer taxol analogues and their
structure activity relationships. Structure modifica-
tions carried out in taxol have been discussed under
the titles of modifications in the side chain at C- ~3,
changes in substituents at other positions of taxane
nucleus, and changes in taxane skeleton. Photoaf-
finity analogues oftaxol and photochemical and elec-
trochemical modifications oftaxol and taxotere have
also been covered.
The physical approach to overcome the solubility
problem of taxol has been its formulation as a 50%
mixture of Cremophor EL (polyethoxylated castor
oil) and 50% alcohol. The drug is then diluted with
saline and administered at doses of 135-250 mg/rrr'
as a 24 hr infusion'", The major drawback of the
formulation is the hypersensitivity reactions caused
by Cremophor EL, which necessitates the use of
prophylactic antiallergic premedications, and the
adoption of longer infusion schedule (24 hr) rather
than short periods. Considerable research is under-
way to utilise liposome as drug carrier to mitigate the
side effects'".
A good amount of success has been achieved in
the synthesis of water soluble taxol analogues by
making modifications in its structure particularly in
the side chain attached at position 13 of the taxane
nucleus.
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Modifications in the Side Chain at C-13 of Taxol
Deutsch et aZ20 have prepared several water-sol-
uble esters (2-4) of the 2' -hydroxy group with impres-
sive biological action. The compounds exhibited
cytotoxicity comparable to or even better than taxol
in assay with B 16 melanoma cells. The compounds,
however, suffer from tendency to release taxol rap-
idly in aqueous media causing precipitation prob-
lems2o. Water-soluble analogues with 2'- hydroxyl
group linked through a succinate group to taurine or
3-amino-l-sulphopropionic acid (5- 7) have been pre-
pared by Kingston et apl. These compounds have
somewhat reduced activity as compared to taxol
though there is 100-200 fold increase in water solu-
bility.
Stella et aP2 have reported to preparation of
methane sulphonate salts of the derivatives of taxol,
such as 8, with amino acids in C-2' and C-7 positions
whose water solubility was greater than 2 mg/mL.
Recently, Nicolaou et aP3 have designed and synthe-
sised a series of water-soluble taxol- releasing deriva-
tives (9-18) (protaxols) with improved pharma-
cological properties. The design of these analogues
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Figure I--Proposed mechanism of taxol release form designed
protaxols; R=taxo! residue.
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21 R1 = ~H11, ~ = Ph
22 R1 = Ph, R2 = ~H11
23 R1 = Ci;H11, R2 = Ci;H11
24 R1 = p-F-Ph, R2 = Ph
release oftaxol from its prodrug. The group substi-
tuted at C-2' to enhance solubility of taxol should
either initiate its own cleavage from the conjugate
and generate taxol in situ (Type I) or the activating
group should be base-labile moiety as certain drug-
resistant tumours have microenvironment of basic
pH (Type II), Type I compounds show considerably
high aqueous solubility while Type II show a little
improvement in solubility. For Type II compounds,
rate of taxol release increases with electron- with-
drawing ability of any substituent while for Type I
compounds rate of release increases with electron-
withdrawing nature of the linking hetero atom. Pro-
taxols have shown potencies similar to taxol against
various cell lines including multiple drug resistant
ovarian (OVCAR-3), lung (H-322) and leukaemia
(MOLT-4) cells. Compound 11 was found to be
particularly promising+'.
French workers, Potier et aP4 have reported the
synthesis of a highly promising taxol analogue
named taxotere (RP56976) docetaxel (19) which is
approximately twice as potent as taxol and more
water soluble. Taxotere has been prepared by semi-
synthesis from IO-deacetylbaccatin III (C IO-DAB
20) and differs from taxol in having the side chain at
C-13 with a tert- butoxycarbonyl moiety in place of
the benzoyl group and the acetoxy group at C-I0
being replaced by a hydroxy group.
Following the success of taxotere, several modifi-
cations in the structure of taxotere were carried out.
Ojima et aP5 modified taxotere at C-3' of the side
chain and C-2' position ofthe nucleus. Introduction
of one cyclohexyl moiety in taxotere does not affect
tubulin binding property. Cytotoxicity of 21 and 22
is eight to twelve times weaker than taxotere against
P388 cell lines. Substitution of two phenyl rings at
C- 3' and C-2 positions with two cyclohexyl groups
as in 23 results in substantial loss of activity in
microtubule disassemblv inhibition but cvtotoxicitv
remains the same as for'21 and 2225. - -
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1 R1 = Ac, ~ = Ph 30 R1 = Co-<J, ~ = Ph
25 R1 = COMe, R2 = (MehCO 31 R1 = CON(Me)2, ~ = Ph
26 R1 = Me, ~ = (MehCO 32 R1 = Me, R2 = Ph
27 R1 = C02Me, ~ = (MehCO 33 R1 = C02Me, R2 = Ph
28 R1 = COPh, R2 = (Me)3CO 34 R1= COPh, R2 = Ph 0
29 R1=COBu,R2=Ph A
Replacement of C-3' phenyl with p-fluorophenyl teft- BuO ~H
with no change in substitution at C-2 gives a vel)'
active taxotere analogue 24. It has an ICso of 0.03
mg/ml, in vitro against P388 leukaemia cell in com-
parison to the ICso oftaxotere as 0.04 mg/mL26.
Changes at C-10 position. Analogues 25-28 of
taxotere with change in functionality at C-IO dis-
played cytotoxic properties. Analogues with C-IO
methyl ether (26) or methyl carbonate (27) are more
cytotoxic than taxol 1 or 10- acetoxytaxofere 25.
They also exhibit better tubulin binding properties.
C-IO modified taxol analogues 29-34 showed tubulin
binding similar to taxol but were less cytotoxic than
the parent compound except the C-I 0 carbamate 3127.
The lO-acetoxy group makes only a small contribu-
tion to the activity of taxol while 10-deoxy series
accentuates the activity oftaxotere. This was proved
by the fact that 10-deacetoxytaxol 35 showed EDso
equivalent to that oftaxol while IO-deoxytaxotere 36
exhibited cytotoxicity better than that from taxotere
in the experiments carried out by Kingston et aP8 It
can thus be inferred that C-IO acetoxy contributes
vel)' little to receptor binding. This observation has
been reinforced by studies carried out by Holton et
aP9 who have reported a simple synthesis of 10-
deacetoxytaxol derivatives: the C-I 0 oxygen substi-
tuent can be reductively removed in high yield by
reactions of taxol, baccatin III or 10- deacetylbac-





Another analogue 37 of taxol where the benzoyl
group was replaced by tert-butoxycarbonyl, as in
taxotere, and the phenyl at C-3' by isobutyl group
showed superior activity than taxol in both tumour






35 R = Ph
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38 R = (MehCO
39 R = Et-C(Me)20
40 R = (MehCNH
41 R =PhNH
The study also surmised that phenyl ring at C-3'
position is not essential for activity, heteroaromatic
ring, alkyl and aikenyl group can serve as replace-
ments. Oxygen at C-3' leads to a less active com-
pound". Recently Ali et aPl have prepared novel
3'- (tert-butyl)-3'-dephenyl analogues of taxol and
taxotere with significantly enhanced water solubility
properties. The most active derivatives found were
the taxotere analogue 38, its homologue 39, and the
urea analogues 40 and 41. All the four analogues
were found to be more cytotoxic than taxol, and the
derivatives 38 and 39 had activity similar to taxotere





42 R1 = (Me)3CO, R2 = Ph, R3 = C6H11
43 R1 = Ph, R2 = C6H11. R3 = Ph







against B 16 melanoma cells. The analogues were
about ninety times more water-soluble than taxol and
four to five times more soluble than taxotere ".
Boge et aP2 have carried out modifications at C-
3' and C-2 positions oftaxol. Analogues 42,43 and
44 displayed better microtubule assembly and S 16
cytotoxicity as compared to taxol, indicating that
none of the aromatic moieties at C-3' or C-2 are
essential for activity. In case of 42, the population of
hydrophobically clustered conformation increases in
polar media, so aromaticity ofC-3' ring appears to be
a significant driving force in the formation of clus-
tered conformation with C-2 ring having much less
effecr'".
The natural stereochemistry (2'R,3'S) of the C-13
N-benzoyl- 3'-phenylisoserine side chain is essential
for activity. 2'-Hydroxyl group is required for strong
microtubule binding+'. Homologues of the C-13 side
chain have been found to be.inactive ". The N-ben-
zoyl can be widely modified and also the 3'-phenyl











46 R = m-F-Ph
47 R = m-CI-Ph
48 R = m-CF3-Ph
49 R = p-F-Ph
50 R = p-MeO-Ph
51 R = p-CF3-Ph
52 R 1 = OH, R2 = Ph
53 R1 = OH, R2 = (MehCO
54 R1 = H, R2 = Ph
Changes at Other Positions of Taxane Nucleus
Changes at C-2 substituents. The a- benzoyloxy
functionality present in taxol appears to play an es-
sential role in binding taxol to its receptors, as its
removal gives 2- deoxytaxol45 which shows modest
in vitro cytotoxicity in human colon cancer cell line.
Its in vitro ability to polymerize tubulin was also
below measurable level". Substitution on m - or
p-position of phenyl ring of the benzoyloxy group of
taxotere gave analogues 46 to 51 which showed
cytotoxicity comparable to taxotere against P3 88 leu-
kaemia cell line".
Changes at C-4 Substituent. The acetyl group
linked to the oxygenated function at C-4 as an ester
seems to be responsible for anchoring hydrophobi-
cally clustered conformation in its proper orientation
which may be essential for activity. This has been
demonstrated by Datta et aP7 and Kingston et aP8,
who in separate studies have shown that 4-deacetyl-
taxol 52 and IO-acetyl-4-deacetyltaxotere 53 have











56 R1 = Ph, R2 = Ph
57 R1 = Furyl, R2 = Ph
58 R1 = Furyl, R2 = (MehCO
very poor activity in the in vitro microtubule binding
assay, human CA46 Burkitt lymphoma cell assay and
tubulin assembly assay Further, a study carried out
by Kingston et 0139 has shown that complete removal
of the oxygenated function as in 4-deacetoxy taxol
54. results in a drastic reduction in the activity. Com-
pound 54 was found to be much less active than taxol
against CA46 Burkitt lymphoma cell and tubulin
assembly assay.
Chen et a/40 have synthesised the C-4 cyclopropyl
ester analogue 55 oftaxol. and in preliminary biologi-
cal evaluation found it to be more potent in vitro than
taxol. Prompted by the encouraging results these
workers have recently synthesised the analogues 56,
57 and 58 in which the C-4 cyclopropyl group was
replaced with an isosteric aziridine ring with an in-
tention that C-4 aziridine ring-bearing analogue 56
could potentially function as an alkylating agent at
the tubulin binding site. The compound, however.
















pared to taxol in the tubulin assay. Other aziridine
analogues 57 and 58 exhibited slightly better poten-
cies than taxol in the same assay"! .
Presence of oxetane ring involving 4- and 5-posi-
tions oftaxane skeleton is crucial for maintaining the
activity; ring opening leads to a drastic decrease in
both disassemble and cytotoxicity 17. Reaction of
taxol with excess triethyloxonium tetrafluoroborate
(Meerwein's reagent) led to the product 59 with an
opened oxetane ring. The product 60 in which
oxetane ring is opened and the ring-A is contracted
was obtained when taxol was treated with acetyl
chloride. Both the derivatives were found to be inac-
tive in tubulin disassembly assay and cytotoxicity
evaluation against KB cells in a cell culture as-
5ay42.43.
A novel taxane structure 61, in which oxetane ring
was not intact and a tetrahydrofuran ring featured,





62 R = H
63 R = M.CO
64 R = PhCO
65 R = o-CH3PhCO






68 R = N3
was obtained when chemoselective debenzoylatiori
of 7,13- diacetylbaccatin was achieved with
tributylin methoxide in NMP in the presence oflith-
ium chloride as an activating agent?".
Changes at C-6 position. Addition of any oxygen-
ated substituent of position-6 of taxol leads to ana-
logues 62 to 66, none of which is as effective as taxol
in promoting the tubulin assembly. However, all
except 62 and 65 stabilised the polymerised tubulin
to the extent equal or better than taxol".
Changes at C-7 Substituent. Hydroxy group at po-
sition-7 of taxol does not significantly interact with
microtubule binding site. This was corraborated by
synthesis of7a.- fluorotaxol67 which showed excel-
lent ability to polymerize tubulin in vitro and dis-
played potent cytotoxicity in HCT -116 cell line 46,47.
However, substitution of C-7 hydroxyl with azido
group or with a double bond at 6,7-position leads to










70 R 1 = OH, R2 = H, R3 = Ph
71 R1 = H, R2 = OH, R3 = (MehCO
72 R1 = H, R2 = H, R3 = (MehCO
69, respectively which are not as effective as taxol in
promoting the tubulin binding but stabilised polym-
erised tubulin better than taxol'". Chen and co- work-
ers" have also observed that C-7 hydroxyl is not
involved in binding and C-l 0 acetate contributes very
little to receptor binding as 7-epi-IO-deoxytaxol 70
displayed potent activity. 7- Deoxytaxotere 71 and
7,10- dideoxytaxotere 72 showed a high level of
cytotoxicity against P388 leukaemia cell and ex-
celled inhibition of disassembly of microtubules,
thus, giving the inference that C-7 hydroxyl and C-
10 oxygenated function (hydroxy or acetoxy) of
taxoids have only secondary effects on the activity'".
Change at C-9 carbonyl. The removal of C-9 car-
bonyl function from the taxane skeleton resulted in
an equally active 9-deoxotaxol 73. Simultaneous re-
moval of the oxygenated function at C-7 and C- 9
affording 74 resultedin a little loss of activity, while
removal of acetoxy function at C-l 0 in addition to the
removal of carbonyl at C-9 and hydroxy at C-7 gave





73 R1 = OH, R2 = OAe
74 R1 = H, R2 = OAe










76 R •• Ph
77 R = (lI.bCO
10- deacetoxyl-7 -deoxy-9- deoxotaxol 75 which was
ten times less active than taxol".
Changes at C-14. Effect on activity of substituting
additional oxygenated function at 14-position of
deacetylated taxol or taxotere has also been studied.
Analogues 76, 77, 78 and 79 possess strong cyto-
toxicity against human breast, non small cell lung,
ovarian and colon cancer cells. Compound 77 exhib-
its activity better than taxol for non small cell lung
cancer (A549) and colon cancer cell lines (HF29) and
substantial activity against adriamycin resistant
breast cancer cell lines (MCF 7-R). These analogues
have also shown improved water solubility, bioavail-
ability and hydrophobicity related drug resistance.
14P-Hydroxy-10-acetylbaccatin isolated from Taxus








78 R = Ph
79 R = (lI_bCO
RO- -
80 R = H
81 R •• Ae
Changes in the Taxane Skeleton. Appendino et al52
prepared the diterpenoid precursors 80 and 81 of
taxol analogues by reduction of the oxidized form of
10-deacetylbaccatin III 20 to' circumvent certain re-
strictions such as inverted cup shape of the taxane
skeleton which makes some of functional groups
unreactive, for example bridge head double bond.
Six-membered C ring of the taxane skeleton is
essential for antitumour activity. Its expansion to
seven-membered ring results in total loss of activity.
The C ring expanded analogue 82 of taxotere was
found to be completely inactive as an inhibitor of
microtubule assembly and displayed no cytotoxic
effect against P388 leukaemia cell line 53 . Introduc-
tion of an ether functionality in C-ring by (2+2)
photocycloaddition, but maintaining its six-mem-
bered character as in analogue 83, however, results
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in retention of activity. The compound 83 mimics the
polarity ofC ring and is biologically active as shown
by in vitro tubulin tesr'".
The taxol derivative 84 with a contracted A ring
has been prepared by treating taxol with mesyl clo-
ride43. It showed comparable activity to taxol in a
tubulin disassembly assay, but did not show signifi-
cant cytotoxicity against KB cells in a cell culture
assay.
Reduction of 11,12 double bound of la-DAB 20
leads to a dihydro derivative which was found to be
less active than la-DAB and taxol in microtubule
assembly assay55 Thus, the II, 12 double bond is
essential for activity.
Photoaffinity Analogues
The molecular mechanism(s) through which taxol
exerts its antitumour effect, both in vivo and in vitro
has been extensively studied during the last decade.
Taxol is a potent inhibitor of cell replication that
blocks cells in the mitotic phase of the cell cycle. It
interferes with the nonnal function of microtubule,












such as colchicine, podophyllotoxin and vinca alka-
loids that inhibit microtubule assembly, taxol pro-
motes the polymerisation of stable microtubules.
This action of'taxol renders microtubules resistant to
depolymerisation and inhibits their normal functions.
To understand the interaction between taxol and mi-
crotubule, a good comprehension of the binding
site(s) for taxol on the microtubule is essential. Pho-
toaffinity analogues of taxol are used as investiga-
tional tools to unravel the binding sites on
microtubules. Such studies also help in the design of
new drugs and analogues with taxol like activity
Photoaffinitv labels at 7-position of taxol were
studied by Kingston et al56 Out of the analogues the
compounds 85 to 88 could be prepared in the radio-
labelled forms. The tritiated version of the compound
appeared to be highly reactive with tubulin. Carboni
et als7 have described the synthesis of a photoaffiniry
analogue 89 of'taxol with 7-hydroxyl group esterified
with 5-azido-2-nitrobenzoic acid. It retained taxol
like activity. Another azide analogue. N-([3.5-3Hl-4-
azidobenzoyl)-N-debenzoyltaxol 90 binds primarily
to p-subunit, only 20% of the incorporated label was
found in u-subunit ".
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The azide analogue 90 exhibited better micro-
tubule assembly activity, greater cytotoxicity to-
wards 1774.2 cells, and more specific and efficient
photo labelling of the p- subunit of tubulin than the
analogue 91 bearing benzophenone- related photore-
active moiety ". Recently, 3'-N-3- (4-benzoyl-
phenyl)propanoyl-3'-N- debenzoyltaxol 92 and its
ditritiated derivative 93 have been prepared and
evaluated for their ability to photolabel tubulin and
P-glycoprotein6o.
Photochemical and Electrochemical Modifica-
tions of Taxol and Taxotere
Promoted by the reports that taxol can function as
a direct photoaffinity labeling agent towards tubulin,
Chen et afl examined the photochemistry oftaxol.
When taxol was irradiated with 254 nm NV light, a
novel pentacyclic taxol isomer 94 was obtained
which contained a new bond between C-3 and C-ll.
Following the successful preparation= of 90.- di-
hydrotaxol by partial synthesis from 13-acetyl-9a.-
dihydrobaccatin III isolated from Taxus canadensis,
and the former analogue proving highly cytotoxic in
vitro. Pulicani et at'3 reported the preparation of
9-dihydro-10-deoxy- and 10- deacetoxy-taxoids by
electrochemical reduction. Taxotere on electro-
chemical reduction in methanol in the presence of
ammonium chloride gave 90.- dihydrotaxotere 95
and 9P- dihydrotaxotere 96. Under the same condi-
tions, the electrochemical reduction of taxol gave
10-deacetoxytaxol. Calcium chloride as well as mag-
nesium and cerium chlorides and to some extent
strontium and lithium chloride favour 10- dehy-
droxylation in the taxotere series. All these taxotere
analogues retained the biological activity.
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